Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia (original) (raw)

References

  1. Grimwade, D. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312–1320 (2001).
    Article CAS Google Scholar
  2. Burnett, A., Wetzler, M. & Lowenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29, 487–494 (2011).
    Article Google Scholar
  3. Westbrook, T.F., Stegmeier, F. & Elledge, S.J. Dissecting cancer pathways and vulnerabilities with RNAi. Cold Spring Harb. Symp. Quant. Biol. 70, 435–444 (2005).
    Article CAS Google Scholar
  4. Bernards, R., Brummelkamp, T.R. & Beijersbergen, R.L. shRNA libraries and their use in cancer genetics. Nat. Methods 3, 701–706 (2006).
    Article CAS Google Scholar
  5. Ngo, V.N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106–110 (2006).
    Article CAS Google Scholar
  6. Whitehurst, A.W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815–819 (2007).
    Article CAS Google Scholar
  7. Turner, N.C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368–1377 (2008).
    Article CAS Google Scholar
  8. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821–834 (2009).
    Article CAS Google Scholar
  9. Gu, T.L. et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 108, 4202–4204 (2006).
    Article CAS Google Scholar
  10. Wang, C., Curtis, J.E., Minden, M.D. & McCulloch, E.A. Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3, 264–269 (1989).
    CAS Google Scholar
  11. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G.F. MET, metastasis, motility, and more. Nat. Rev. Mol. Cell Biol. 4, 915–925 (2003).
    Article CAS Google Scholar
  12. Valk, P.J. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617–1628 (2004).
    Article CAS Google Scholar
  13. Zou, H.Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408–4417 (2007).
    Article CAS Google Scholar
  14. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896–5904 (1998).
    Article CAS Google Scholar
  15. Sporn, M.B. & Todaro, G.J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303, 878–880 (1980).
    Article CAS Google Scholar
  16. Loriaux, M.M. et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111, 4788–4796 (2008).
    Article CAS Google Scholar
  17. Haq, R. et al. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res. 62, 5076–5082 (2002).
    CAS Google Scholar
  18. Majeti, R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. USA 106, 3396–3401 (2009).
    Article CAS Google Scholar
  19. Robinson, D.R., Wu, Y.M. & Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene 19, 5548–5557 (2000).
    Article CAS Google Scholar
  20. Zheng, R., Klang, K., Gorin, N.C. & Small, D. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk. Res. 28, 121–126 (2004).
    Article CAS Google Scholar
  21. Zhou, J. et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113, 4052–4062 (2009).
    Article CAS Google Scholar
  22. Sato, T. et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117, 3286–3293 (2011).
    Article CAS Google Scholar
  23. Ngo, V.N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106–110 (2006).
    Article CAS Google Scholar
  24. Heinrichs, S. et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23, 1605–1613 (2009).
    Article CAS Google Scholar
  25. Mathew, P. et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 3, 105–109 (2001).
    Article CAS Google Scholar
  26. Armstrong, S.A. et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173–183 (2003).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank A. Gutierrez, M. Mansour and E. Gjini for critical discussions and J. Gilbert for editorial advice. This research was supported by the US National Institutes of Health grant K08CA160660 (A.K.), the William Lawrence and Blanche Hughes Foundation (T.S.), the Samuel Waxman Cancer Research Foundation (J.D.L.), the V Foundation (A.T.L.) and the Intramural Research Program of the National Cancer Institute, Center for Cancer Research (L.M.S.).

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Alex Kentsis, Casie Reed, Takaomi Sanda, Amanda Christie, Lisa A Moreau, Andrew L Kung & A Thomas Look
  2. Division of Hematology and Oncology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Alex Kentsis, Casie Reed, Takaomi Sanda, Amanda Christie, Lisa A Moreau, Andrew L Kung & A Thomas Look
  3. Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Kim L Rice & Jonathan D Licht
  4. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Scott J Rodig & Jeffery L Kutok
  5. Department of Haematology, Manchester Royal Infirmary, Central Manchester University Hospitals National Health Service Foundation Trust, and Manchester Academic Health Science Centre, Manchester, UK
    Eleni Tholouli & Richard J Byers
  6. Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    Amanda Christie & Andrew L Kung
  7. Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Peter J M Valk & Ruud Delwel
  8. Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California, USA
    Vu Ngo
  9. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    Suzanne E Dahlberg
  10. School of Cancer and Enabling Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
    Richard J Byers
  11. Department of Research Pharmacology, Pfizer Global Research and Development, La Jolla, California, USA
    James G Christensen
  12. Department of Molecular Oncology, Van Andel Research Institute, Grand Rapids, Michigan, USA
    George Vande Woude
  13. Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Louis M Staudt

Authors

  1. Alex Kentsis
  2. Casie Reed
  3. Kim L Rice
  4. Takaomi Sanda
  5. Scott J Rodig
  6. Eleni Tholouli
  7. Amanda Christie
  8. Peter J M Valk
  9. Ruud Delwel
  10. Vu Ngo
  11. Jeffery L Kutok
  12. Suzanne E Dahlberg
  13. Lisa A Moreau
  14. Richard J Byers
  15. James G Christensen
  16. George Vande Woude
  17. Jonathan D Licht
  18. Andrew L Kung
  19. Louis M Staudt
  20. A Thomas Look

Contributions

A.K., C.R., K.L.R., T.S., A.C., E.T., V.N. and L.A.M. performed experiments. A.K., S.J.R., P.J.M.V., R.D., J.L.K., S.E.D., R.J.B., J.G.C., G.V.W., J.D.L., A.L.K., L.M.S. and A.T.L. analyzed data. A.K. and A.T.L. wrote the manuscript.

Corresponding author

Correspondence toA Thomas Look.

Ethics declarations

Competing interests

J.G.C. is an employee of Pfizer.

Supplementary information

Rights and permissions

About this article

Cite this article

Kentsis, A., Reed, C., Rice, K. et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.Nat Med 18, 1118–1122 (2012). https://doi.org/10.1038/nm.2819

Download citation